MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia [20]

Leukemia

Volumn 20, Issue 1, 2006, Pages 179-182

  Stam, R W ^a   Hubeek, I ^b   den Boer, M L ^a   Buijs Gladdines, J G C A M ^a   Creutzig, U ^c   Kaspers, G J L ^b   Pieters, R ^a,d  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AML BFM Study Group   (Germany)

^d Interfant 99 Collaborative Study Group

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 19; CHROMOSOME BAND; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE REARRANGEMENT; HUMAN; IN VITRO STUDY; INFANT; LETTER; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

EID: 33644987431     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404031     Document Type: Letter

References (5)

1. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukaemia - implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
2. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004; 18: 521-529.
3. Amici A, Emanuelli M, Magni G, Raffaelli N, Ruggieri S. Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides. FEBS Lett 1997; 419: 263-267.
4. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 1270-1276.
5. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002; 100: 3352-3360.